Compare Nasdaq100 ETF (QQQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Smith & Nephew plc — how do they compare? Nasdaq100 ETF trades at $751.27 (market cap $506.92B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Nasdaq100 ETF is far larger — about 45.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Smith & Nephew plc for 121 Days on average.
| QQQ | SNN | |
|---|---|---|
Market Cap | $506.92B | $11.10B |
Volume | 48,326,518 | 1,051,703 |
52-Week High | $759.66 | $37.17 |
52-Week Low | $558.34 | $26.42 |
Typical Hold Time | 162 Days | 121 Days |
Sector | — | Health |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $747.64, down 1.33% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite mixed analyst sentiment. Recent news highlights QQQ's concentration in technology stocks and ongoing comparisons with lower-cost alternatives like VOO and QQQM.
The outlook remains positive given QQQ's exposure to leading tech innovators and AI-driven growth potential, though elevated valuations and interest rate sensitivity present near-term risks. Long-term growth prospects appear solid, but investors should monitor concentration risk and fee differentials among competing ETFs.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
